Exploring the Growing Influenza Diagnostics Market 2021-2026: What You Need to Know

The Influenza Diagnostics Market is a rapidly growing sector, with technological advancements and increasing awareness about the disease driving the growth of the market. Influenza, commonly known as the flu, is a viral infection that can cause mild to severe symptoms. Early diagnosis and treatment of the flu is essential for preventing its spread and reducing the risk of complications. The global Influenza Diagnostics Market is estimated to grow at a compound annual growth rate of 7.7% from 2021 to 2026.

Currently, Influenza Diagnostics Market is projected to reach USD 1.1 billion by 2026 from USD 0.8 billion in 2021, Rising demand for rapid disease diagnosis, increasing prevalence of influenza and growth in influenza research for diagnostic technologies are among the other factors. Emerging economies such as India and Japan are providing lucrative opportunities for the players operating in the influenza diagnostics market.

What is Influenza?

Influenza is a contagious viral respiratory illness that affects the nose, throat, and lungs. Its symptoms include fever, cough, sore throat, muscle or body aches, headaches, fatigue, and sometimes vomiting or diarrhea. Influenza is spread through the air when an infected person coughs or sneezes, and can also be spread by contact with surfaces or objects. People with the flu can be contagious from the day before symptoms start to up to five days after becoming sick.

What are Influenza Diagnostics?

Influenza diagnostics are tests used to detect the influenza virus in a person. These tests can help diagnose and monitor the progression of the flu and allow for early treatment. Common tests used for influenza diagnosis include Rapid Influenza Diagnostic Test (RIDT), Reverse Transcription Polymerase Chain Reaction (RT-PCR), and virus culture.

Request for assumptions & how numbers were triangulated.


Market Growth Drivers:

The Influenza Diagnostics Market is expected to witness significant growth over the next few years, due to a number of factors. Increasing awareness about the disease, technological advancements in diagnostics, and increased demand for home-based diagnostics are driving the market growth. Additionally, the growing prevalence of influenza and the rising need for early diagnosis and treatment are expected to boost the market.

Key Market Players:

The major players in this market are Danaher Corporation (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), F. Hoffmann-LA Roche AG (Switzerland), Abbott Laboratories, Inc. (Us), Hologic, Inc. (US), bioMérieux SA (France), Quidel Corporation (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), GenMark Diagnostics, Inc. (US), Luminex Corporation (US), Tecan Trading AG (Switzerland), DiaSorin SA (Italy), altona Diagnostics GmbH (Germany), SEKISUI Diagnostics (US), SA Scientific Ltd. (US), Coris BioConcept SPRL (Belgium), ELITech Group (France), Mast Group Ltd. (UK), Genome Diagnostics, Pvt. Ltd. (India), Germaine Laboratories, Inc. (US), Response Biomedical Corp. (Canada). Tauns Laboratories, Inc. (Japan) and 3B BlackBio Biotech India Ltd. (India)

The Influenza Diagnostics Market is set to witness significant growth in the coming years, driven by increasing awareness about the disease, technological advancements in diagnostics, and increased demand for home-based diagnostics. With the growing prevalence of influenza, early diagnosis and treatment of the flu is essential for preventing its spread and reducing the risk of complications.

Download an Illustrative Overview:


Recent Developments

  • In May 2021 Becton, Dickinson and Company (US) received FDA approval for the BD Veritor Plus System, which is used to detect SARS-CoV-2, influenza A, and influenza B.
  • In March 2021, Abbott Laboratories, Inc. (US) received emergency use authorization (EUA) from the FDA for a laboratory PCR assay that detects and differentiates SARS-COV-2, flu A, flu B, and RSV in one test.
  • In February 2021, Becton, Dickinson and Company (US) received approval from the FDA for the emergency use authorization (EUA) for a new molecular diagnostic test for both SARS-CoV-2 and influenza A+B.

Content Source: